Gonna Somu Naidu

Gonna Somu Naidu

Auto-generated profile, based on publicly available information

Gonna Somu Naidu

Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Science Advances
Verified
Journal Article
Closed access
EKEdo Kon
Edo Kon
YLYinon Levy
Yinon Levy
UEUri Elia
Uri Elia
HCHila Cohen
Hila Cohen
IHInbal Hazan-Halevy
Inbal Hazan-Halevy
OCOfer Cohen
Ofer Cohen
Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform’s effectiveness against bacterial pathogens are limited. Here, we developed an effective mRNA-LNP vaccine against a lethal bacterial pathogen by optimizing mRNA payload guanine and cytosine content and antigen design. We designed a nucleoside-modified mRNA-LNP vaccine based on the bacterial F1 capsule antigen, a major protective component of Yersinia pestis , the etiological agent of plague. Plague is a rapidly deteriorating contagious disease that has killed millions of people during the history of humankind. Now, the disease is treated effectively with antibiotics; however, in the case of a multiple-antibiotic-resistant strain outbreak, alternative countermeasures are required. Our mRNA-LNP vaccine elicited humoral and cellular immunological responses in C57BL/6 mice and conferred rapid, full protection against lethal Y. pestis infection after a single dose. These data open avenues for urgently needed effective antibacterial vaccines.

6 February 2025 in ACS Nano
Verified
Journal Article
Open access
GNGonna Somu Naidu
Gonna Somu Naidu
Riccardo RampadoRiccardo Rampado
Riccardo Rampado
PSPreeti Sharma
Preeti Sharma
AEAssaf Ezra
Assaf Ezra
GKGovinda Reddy Kundoor
Govinda Reddy Kundoor
Dan PeerDan Peer
Dan Peer
Lipid nanoparticles (LNPs) have emerged as a groundbreaking delivery system for vaccines and therapeutic mRNAs. Ionizable lipids are the most pivotal component of LNPs due to their ability to electrostatically interact with mRNA, allowing its encapsulation while concurrently enabling its endosomal escape following cellular internalization. Thus, extensive research has been performed to optimize the ionizable lipid structure and to develop formulations that are well tolerated and allow efficient targeting of different organs that result in a high and sustained mRNA expression. However, one facet of the ionizable lipids' structure has been mostly overlooked: the linker segment between the ionizable headgroup and their tails. Here, we screened a rationally designed library of ionizable lipids with different biodegradable linkers. We extensively characterized LNPs formulated using these ionizable lipids and elucidated how these minor structural changes in the ionizable lipids structure radically influenced the LNPs' biodistribution in vivo. We showed how the use of amide and urea linkers can modulate the LNPs' pKa, resulting in an improved specificity for lung transfection. Finally, we demonstrated how one of these lipids (lipid 35) that form LNPs entrapping a bacterial toxin [pseudomonas exotoxin A (mmPE)] in the form of an mRNA reduced tumor burden and significantly increased the survival of mice with lung metastasis.

7 April 2023 in Science Advances
Verified
Journal Article
Open access
SCSushmita Chatterjee
Sushmita Chatterjee
GNGonna Somu Naidu
Gonna Somu Naidu
IHInbal Hazan-Halevy
Inbal Hazan-Halevy
HGHanna Grobe
Hanna Grobe
AEAssaf Ezra
Assaf Ezra
Dan PeerDan Peer
Dan Peer
The potential of microtubule-associated protein targets for cancer therapeutics remains largely unexplored due to the lack of target-specific agents. Here, we explored the therapeutic potential of targeting cytoskeleton-associated protein 5 (CKAP5), an important microtubule-associated protein, with CKAP5 -targeting siRNAs encapsulated in lipid nanoparticles (LNPs). Our screening of 20 solid cancer cell lines demonstrated selective vulnerability of genetically unstable cancer cell lines in response to CKAP5 silencing. We identified a highly responsive chemo-resistant ovarian cancer cell line, in which CKAP5 silencing led to significant loss in EB1 dynamics during mitosis. Last, we demonstrated the therapeutic potential in an in vivo ovarian cancer model, showing 80% survival rate of si CKAP5 LNPs-treated animals. Together, our results highlight the importance of CKAP5 as a therapeutic target for genetically unstable ovarian cancer and warrants further investigation into its mechanistic aspects.

18 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SQShahd Qassem
Shahd Qassem
GNGonna Somu Naidu
Gonna Somu Naidu
MGMeir Goldsmith
Meir Goldsmith
DBDor Breier
Dor Breier
RRRiccardo Rampado
Riccardo Rampado
Dan PeerDan Peer
Dan Peer
Locked nucleic acids are a third-generation antisense oligonucleotides with high binding affinity. A major limitation is the high dosages they require to achieve efficacy which may induce unwanted adverse effects. Here, we report the use of Lipid-based nanoparticles to deliver locked nucleic acids for treating intestinal inflammation in mice. Eight formulations with novel ionizable lipids were screened for stability and toxicity. Particles were loaded with splice-switcher sequence, enabling a precise assessment of potency in vitro. Three lead candidates were tested in vivo, demonstrating a 30-fold dose reduction compared to the unformulated oligonucleotides. The most potent formulation, encapsulating a sequence against Tumor necrosis factor alpha, was evaluated in a mouse model of colitis. Treatment reduced disease severity and inflammatory cytokines, with good safety. These findings support the use of lipid nanoparticles for the precise delivery of locked nucleic acids and highlight their promise for future therapies.

22 August 2025 in ACS Nanoscience Au
Verified
Journal Article
Open access
SMStefania Mamberti
Stefania Mamberti
CPCristiano Pesce
Cristiano Pesce
GAGreta Avancini
Greta Avancini
GNGonna Somu Naidu
Gonna Somu Naidu
GKGovinda Reddy Kundoor
Govinda Reddy Kundoor
RPRoberto Palomba
Roberto Palomba
Lipid nanoparticles (LNP) have been extensively studied for their ability to encapsulate and protect RNA molecules from degradation. More recently, a few studies have begun to explore their applications as carriers for brain drug delivery via various administration routes. Nose-to-brain delivery represents a promising alternative to both invasive local injections and systemic administration, offering the possibility to bypass the blood-brain barrier and directly access the brain, achieve rapid absorption, reduce systemic exposure, and allow for ease of administration. In order to evaluate the viability of this alternative route, it is essential to acquire a better understanding of the intraneuronal mass transport of LNP, particularly in terms of how effectively and efficiently they deliver their payloads from the periphery to neuronal cell bodies. However, most previous studies have focused primarily on the delivery vector itself rather than on the fate of the transported cargo. In this study, we investigate the retrograde trafficking of nucleic acid-loaded LNP in primary cortical neurons, focusing on the transport of both the particle and the payload. Three distinct LNP were formulated to characterize different aspects of their interaction with the cells, with the major LNP player of this study containing a red-fluorescent Rhodamine B-tagged lipid and a green fluorescently FAM-tagged RNA. Flow cytometry was used to document LNP uptake by primary cortical neurons over time. Additionally, confocal microscopy was then used to investigate the colocalization of LNP and RNA after a conventional 2D culture treatment. As a final step, a compartmentalized chip that separates the somal and the axonal regions of cortical neurons was used to study the intraneuronal dynamics of LNP and their cargo. In this second setup, LNP were selectively administered at the axonal compartment, and the fluorescent signals from the vector (red) and the payload (green) were imaged through time-lapse microscopy. The progressive accumulation of RNA found at cellular bodies also in the absence of the red signal suggested an efficient retrograde transport of the LNP payload toward the soma. Comprehensively, this work demonstrates that primary cortical neurons are capable of efficiently uptaking LNP and of intracellularly transporting both LNP and their RNA cargo. Interestingly, a different colocalization trend (LNP-RNA) emerged depending on the followed setup. Localized axonal transfection appeared to favor dissociation of RNA from the LNP and subsequent accumulation at the soma. Overall, our work provides a fundamental in vitro proof of concept of the RNA delivery to the cellular bodies of primary cortical neurons via the retrograde transport of LNP vectors administered at the axonal termini. This finding, together with the image-analysis-based quantification of the RNA accumulation described in our work, paves the way for future studies aimed at designing lipid-based nanoparticles for RNA therapeutic delivery to the brain via peripheral administration.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
MHMinki Ha
Minki Ha
JKJaehyun Kim
Jaehyun Kim
SKSeyoung Kim
Seyoung Kim
GNGonna Somu Naidu
Gonna Somu Naidu
SCSUNGCHAN CHO
SUNGCHAN CHO
SYSeok‐Beom Yong
Seok‐Beom Yong
MRNA‐encapsulated lipid nanoparticles (LNPs) have been used to develop vaccines and therapeutics since the COVID‐19 pandemic, and clinical studies have demonstrated therapeutic benefits of mRNA vaccines for various cancers. However, current LNP formulations still require functional modifications to tailor them for therapeutic and vaccine applications. Recently, fifth component‐incorporated LNPs were developed to finely tune their functionality, including immunogenicity and organ‐targeting ability. Here, biphenyl‐structured amphiphilic PDL1 inhibitors are employed as a fifth component to modify LNPs. Amphiphilic PDL1 inhibitor‐incorporated, ALC0315‐based LNPs show higher lymph node targeting, with a 6.94‐fold increase in mRNA expression in the inguinal lymph node, thereby improving lymph node expansion and immune cell infiltration and, consequently, inducing greater mRNA vaccine efficacy. Furthermore, a consistent lymph node‐targeting effect of the fifth component‐containing LNP was observed across studies using the SM102‐based LNP formulation, suggesting its universality. In conclusion, this study demonstrates that PDL1 inhibitor‐incorporated fifth‐component LNP serves as a next‐generation platform for mRNA vaccines.